The Latest Breaking News from Eli Lilly

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).  Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval.  The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

Participants in the trial lost an average of 22.5 per cent of their body weight. This is more than twice the normal effectiveness of such treatments and could be an alternative to surgery for people living with obesity.

The market correction suffered a violent sell-off late in the week. Apple is a relative winner but an absolute loser.

With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.

Heavy demand for pesticides and fertilizers has led to strength in IBD's agricultural chemicals industry group.

With the market searching for a bottom, Tesla, Microsoft, Eli Lilly and other leading stocks try to recharge as May kicks off.

A cardiologist who helped invent an automatic implantable defibrillator that has helped countless heart patients live longer and healthier has died

Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.